Mild Cognitive Impairment (MCI): Predicting Conversion to Clinically Probable Alzheimer’s Disease with Fluoro-Deoxy-Glucose PET

Optimal implementation of disease-modifying treatment for sporadic Alzheimer’ s disease (AD) will require detection of patients at the pre-dementia stage. Resting-state mapping of brain glucose utilization with PET and 18F-fluorodeoxy-glucose (FDG) is sensitive to early changes in synaptic activity/density in neurodegenerative diseases such as AD. In this study, we assessed memory-impaired patients with mild cognitive impairment (MCI) and used voxel-based analysis to search for an FDG-PET profile associated with rapid conversion to AD.